European Journal of Cancer Oncology

Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →